Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Dose-Ranging Study of the Safety and Efficacy of ADX415 Immediate-Release in the Treatment of Essential Hypertension

NCT00779181 is registered in ClinicalTrials.gov with Addrenex Pharmaceuticals, Inc. as lead sponsor.

NCT NCT00779181
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00779181 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Dose-Ranging Study of the Safety and Efficacy of ADX415 Immediate-Release in the Treatment of Essential Hypertension
Lead sponsor
Addrenex Pharmaceuticals, Inc.
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2008
Completion date
December 31, 2008
Enrollment
80 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

hypertension